A phase 3, randomized, double-blind, placebo controlled, multicenter trial to evaluate the safety and efficacy of BMS-298585 [muraglitazar] in combination with glyburide [glibenclamide] therapy in subjects with type 2 diabetes who have inadequate glycemic control on sulfonylurea therapy alone

Trial Profile

A phase 3, randomized, double-blind, placebo controlled, multicenter trial to evaluate the safety and efficacy of BMS-298585 [muraglitazar] in combination with glyburide [glibenclamide] therapy in subjects with type 2 diabetes who have inadequate glycemic control on sulfonylurea therapy alone

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Sep 2010

At a glance

  • Drugs Glibenclamide; Muraglitazar
  • Indications Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms PPAR-COMBO
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 02 Nov 2006 Status change
    • 31 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top